The global bioanalytical testing services market is
anticipated to reach USD 3.0 billion by 2025, according to a new report by
Grand View Research, Inc. The performance of market players in bioanalytical
testing domain is highly influenced by the level of demand from end-user side.
Due to intense market efforts, increasing awareness level, improving
accessibility, and government initiatives, consumers, these days, are more
concerned about self-care, resulting in higher consumption of pharmaceutical
products.
There is a major price difference
observed between conducting analytical tests in-house and outsourcing. A
company may lack the required set-up and expertise to perform every possible
test in-house. In addition, there are serval no routine activities that are
needed to be performed only once. These include registration stability storage
& testing, process & facility validation work, cleaning validations,
analytical testing using expensive equipment & method development.
The bioanalytical testing
services market based on molecule type is bifurcated into small molecule
testing and large molecule testing. Small molecule bioanalytical testing held a
lucrative share in 2016. Most of the generic and branded drug compounds are of
small molecule category. Additionally, with the patent expiration many
blockbuster drugs, generic manufacturers are required to conduct and submit
bioanalytical testing results. These factors primarily governed the growth of
the small molecule drug bioanalytical testing market. On the contrary, large
molecule bioanalytical testing services are anticipated to exhibit healthy
growth over the forecast period. This can be attributed to a rich pipeline of
biologics or amino acid based products.
U.S. bioanalytical testing services market, by large
molecule-type, 2014 - 2025 (USD Million)
Browse full research report on Bioanalytical
Testing Services Market
Further key findings from the report suggest:
- Large
molecule bioanalytical testing services are anticipated to exhibit healthy
growth over the forecast period. This can be attributed to a rich pipeline
of biologics or amino acid based products
- LC-MS studies
are vital in bioanalysis of large molecules. They can be used for various
methods such as development & validation, preclinical & clinical
sample analysis, immunoanalytical solutions, and microfluidic tests for
biologics
- In vivo ADME
is designed to assess biopharmaceutical characteristic of a drug at
preclinical level. Service providers offer customized study on variety of
species. QWBA, mass balance, excretion, expired air collection in rodents,
metabolite profiling, and radioactivity sample analysis are the key
studies offered
- North America
dominated the global bioanalytical testing services market in 2016. This
can be attributed to the fact that it is one of the top manufacturing hubs
of highly reliable, complex, and high-end pharmaceuticals
- Some of the
key players in this market include PPD, ICON plc., Covance Inc., LabCorp,
Charles River Laboratories International, Inc., inVentiv Health, SGS SA,
Toxikon, Inc., Intertek group, and Pace Analytical Services,
LLC.Collaborations, service portfolio expansion and merger &
acquisitions are key strategic undertakings by these players
For more information: http://www.grandviewresearch.com
No comments:
Post a Comment